Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more
Biovica International AB (publ) (BIOVIC-B) - Net Assets
Latest net assets as of July 2025: Skr25.68 Million SEK
Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) has net assets worth Skr25.68 Million SEK as of July 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr56.82 Million) and total liabilities (Skr31.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr25.68 Million |
| % of Total Assets | 45.2% |
| Annual Growth Rate | 13.86% |
| 5-Year Change | -76.35% |
| 10-Year Change | 69.57% |
| Growth Volatility | 102.89 |
Biovica International AB (publ) - Net Assets Trend (2014–2025)
This chart illustrates how Biovica International AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biovica International AB (publ) (2014–2025)
The table below shows the annual net assets of Biovica International AB (publ) from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | Skr43.21 Million | -55.29% |
| 2024-04-30 | Skr96.64 Million | -30.29% |
| 2023-04-30 | Skr138.64 Million | +11.72% |
| 2022-04-30 | Skr124.09 Million | -32.07% |
| 2021-04-30 | Skr182.66 Million | +133.53% |
| 2020-04-30 | Skr78.22 Million | +50.14% |
| 2019-04-30 | Skr52.10 Million | -29.32% |
| 2018-04-30 | Skr73.71 Million | -19.48% |
| 2017-04-30 | Skr91.55 Million | +259.30% |
| 2016-04-30 | Skr25.48 Million | +206.39% |
| 2015-04-30 | Skr8.32 Million | -19.76% |
| 2014-04-30 | Skr10.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biovica International AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52122509700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr6.52 Million | 15.09% |
| Other Components | Skr577.60 Million | 1336.86% |
| Total Equity | Skr43.21 Million | 100.00% |
Biovica International AB (publ) Competitors by Market Cap
The table below lists competitors of Biovica International AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orcoda Ltd
AU:ODA
|
$2.57 Million |
|
Morenzo Abadi Perkasa Tbk Pt
JK:ENZO
|
$2.57 Million |
|
Seacera Group Bhd
KLSE:7073
|
$2.57 Million |
|
Bitros Holding S.A
AT:MPITR
|
$2.57 Million |
|
Nord.investments A/S
CO:NORD
|
$2.56 Million |
|
Equity Development Investment
JK:GSMF
|
$2.56 Million |
|
Patagonia Lithium Ltd
AU:PL3
|
$2.56 Million |
|
Prime Energy PE Ltd
TA:PRIM
|
$2.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biovica International AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 96,641,000 to 43,206,000, a change of -53,435,000 (-55.3%).
- Net loss of 87,624,000 reduced equity.
- Share repurchases of 34,233,000 reduced equity.
- New share issuances of 35,837,000 increased equity.
- Other comprehensive income decreased equity by 410,000.
- Other factors increased equity by 32,995,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-87.62 Million | -202.81% |
| Share Repurchases | Skr34.23 Million | -79.23% |
| Share Issuances | Skr35.84 Million | +82.94% |
| Other Comprehensive Income | Skr-410.00K | -0.95% |
| Other Changes | Skr32.99 Million | +76.37% |
| Total Change | Skr- | -55.29% |
Book Value vs Market Value Analysis
This analysis compares Biovica International AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.60x to 0.75x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-04-30 | Skr0.58 | Skr0.35 | x |
| 2015-04-30 | Skr0.47 | Skr0.35 | x |
| 2016-04-30 | Skr1.43 | Skr0.35 | x |
| 2017-04-30 | Skr5.04 | Skr0.35 | x |
| 2018-04-30 | Skr4.06 | Skr0.35 | x |
| 2019-04-30 | Skr2.76 | Skr0.35 | x |
| 2020-04-30 | Skr3.09 | Skr0.35 | x |
| 2021-04-30 | Skr5.98 | Skr0.35 | x |
| 2022-04-30 | Skr4.06 | Skr0.35 | x |
| 2023-04-30 | Skr3.74 | Skr0.35 | x |
| 2024-04-30 | Skr1.65 | Skr0.35 | x |
| 2025-04-30 | Skr0.47 | Skr0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biovica International AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -202.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1016.64%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.50x
- Recent ROE (-202.81%) is below the historical average (-63.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -51.83% | -132.80% | 0.28x | 1.39x | Skr-6.41 Million |
| 2015 | -84.69% | -1534.42% | 0.03x | 2.14x | Skr-7.87 Million |
| 2016 | -19.75% | -206.87% | 0.08x | 1.13x | Skr-7.58 Million |
| 2017 | -16.23% | -2350.79% | 0.01x | 1.06x | Skr-24.01 Million |
| 2018 | -24.51% | -663.39% | 0.03x | 1.10x | Skr-25.44 Million |
| 2019 | -41.38% | -717.34% | 0.05x | 1.17x | Skr-26.77 Million |
| 2020 | -38.76% | -1814.36% | 0.02x | 1.15x | Skr-38.14 Million |
| 2021 | -21.62% | -1900.96% | 0.01x | 1.05x | Skr-57.75 Million |
| 2022 | -48.35% | -2934.13% | 0.01x | 1.22x | Skr-72.41 Million |
| 2023 | -79.70% | -3265.13% | 0.02x | 1.24x | Skr-124.36 Million |
| 2024 | -129.16% | -1712.25% | 0.06x | 1.36x | Skr-134.49 Million |
| 2025 | -202.81% | -1016.64% | 0.13x | 1.50x | Skr-91.94 Million |
Industry Comparison
This section compares Biovica International AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biovica International AB (publ) (BIOVIC-B) | Skr25.68 Million | -51.83% | 1.21x | $2.57 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |